Johnson & Johnson (BSP:JNJB34) Short-Term Debt: R$59,911 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

BSP:JNJB34 Johnson & Johnson BSP:JNJB34
80 GF Score
Price R$93.91
GF Value R$66.62
Valuation Significantly Overvalued
! 7 Warning Signs
View Full Analysis

What is Johnson & Johnson Short-Term Debt?

Johnson & Johnson BSP:JNJB34 +0.04% 80 Short-Term Debt is R$59,911 Mil as of Jun. 2026. GuruFocus rates BSP:JNJB34 with a GF Score™ of 80/100 and a GF Value™ of R$66.62 (Significantly Overvalued). The stock has 7 warning signs investors should review.

Johnson & Johnson's Short-Term Debt for the quarter that ended in Jun. 2026 was R$59,911 Mil.

Johnson & Johnson's quarterly Short-Term Debt increased from Dec. 2025 (R$46,346 Mil) to Mar. 2026 (R$91,309 Mil) but then declined from Mar. 2026 (R$91,309 Mil) to Jun. 2026 (R$59,911 Mil).

Johnson & Johnson's annual Short-Term Debt increased from Dec. 2023 (R$16,909 Mil) to Dec. 2024 (R$36,502 Mil) and increased from Dec. 2024 (R$36,502 Mil) to Dec. 2025 (R$46,346 Mil).

Johnson & Johnson Short-Term Debt Explanation

Short-Term Debt represents the total amount of Long-Term Debt such as bank loans and commercial paper, which is due within one year.

Johnson & Johnson Short-Term Debt Related Terms

Johnson & Johnson Short-Term Debt Historical Data

* Premium members only.

The historical data trend for Johnson & Johnson's Short-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Johnson & Johnson Short-Term Debt Chart

Johnson & Johnson Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Short-Term Debt
Get a 7-Day Free Trial Premium Member Only Premium Member Only 21,296.35 66,910.32 16,909.21 36,502.28 46,346.17

Johnson & Johnson Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Short-Term Debt Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 63,920.89 34,253.48 46,346.17 91,308.82 59,910.98
BSP:JNJB34
80GF Score
Johnson & Johnson BSP:JNJB34
Short-Term Debt is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Short-Term Debt →
What does a Short-Term Debt of R$59,911 Mil mean?
Johnson & Johnson (BSP:JNJB34) has a Short-Term Debt of R$59,911 Mil as of Jun. 2026.
Is Johnson & Johnson's Short-Term Debt too high?
Johnson & Johnson's current Short-Term Debt is R$59,911 Mil. Overall, Johnson & Johnson has a GF Score™ of 80/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Johnson & Johnson's Short-Term Debt compare to ABBV and MRK?
Johnson & Johnson's Short-Term Debt of R$59,911 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Short-Term Debt for a Drug Manufacturers company?
A good Short-Term Debt depends on the Drug Manufacturers industry context. However, Short-Term Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Short-Term Debt mean?
A high Short-Term Debt can signal that a stock is expensive relative to its fundamentals. Johnson & Johnson's current Short-Term Debt is R$59,911 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Johnson & Johnson stock overvalued right now?
Based on GuruFocus' analysis, Johnson & Johnson (BSP:JNJB34) is currently considered Significantly Overvalued. The stock's GF Value™ is R$66.62, compared to a current price of R$93.91 — trading 41% above its estimated fair value. The current Short-Term Debt is R$59,911 Mil. Johnson & Johnson's overall GF Score™ is 80/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Short-Term Debt calculated?
Short-Term Debt is calculated from a company's financial statements. For Johnson & Johnson (BSP:JNJB34), the current Short-Term Debt is R$59,911 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Johnson & Johnson (BSP:JNJB34) Overvalued in 2026?

Based on GuruFocus' analysis, Johnson & Johnson stock appears to be overvalued. The current stock price of R$93.91 is trading 41% above its estimated GF Value™ of R$66.62. GuruFocus considers Johnson & Johnson to be Significantly Overvalued.

Key valuation signals for BSP:JNJB34:

  • Short-Term Debt: R$59,911 Mil
  • GF Value™: R$66.62 vs. price of R$93.91 (41% above fair value)
  • GF Score™: 80/100 with 7 warning signs

No single metric tells the full story. See the BSP:JNJB34 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Johnson & Johnson Business Description

Address One Johnson & Johnson Plaza, New Brunswick, NJ, USA, 08933
Johnson & Johnson is the world's largest and most diverse healthcare firm. It has two divisions: innovative medicine and medtech. These now represent all of the company's sales following the divestment of the consumer business, Kenvue, in 2023. After restructurings in 2023-24, the drug division focuses on three main therapeutic areas: immunology, oncology, and neurology. Geographically, just over half of total revenue is generated in the United States.
80GF Score

Get the complete analysis for BSP:JNJB34

Short-Term Debt is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

R$93.91
Price
R$66.62
GF Value